# Phase 2 Alzheimer Disease trials recruiting: 71 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 71 trials in phase 2 for Alzheimer Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Alzheimer Disease trials: 71 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/alzheimer-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 71
- Recruiting or not yet: 71
- Read on: November 19, 2026

## Trials

The 25 newest of 71, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07905352 | A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905352) |
| October 14, 2026 | NCT07873463 | Flutemetamol F 18 Injection Formulation Comparison | GE Healthcare | Phase 2 | Recruiting | Cognitive Dysfunction | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873463) |
| September 22, 2026 | NCT07832383 | Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor | Neurocrine Biosciences | Phase 2 | Not yet recruiting | Alzheimer's Disease | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832383) |
| September 18, 2026 | NCT07827768 | AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease | Institute for Molecular Medicine | Phase 2 | Not yet recruiting | Preclinical Alzheimer's Disease, Alzheimer Disease | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827768) |
| September 1, 2026 | NCT07796308 | Terazosin And Metabolic Engagement in Alzheimer's Disease | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Alzheimer s Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796308) |
| August 31, 2026 | NCT07794670 | Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease | NewAmsterdam Pharma | Phase 2 | Recruiting | Preclinical Alzheimer's Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794670) |
| August 24, 2026 | NCT07781657 | Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 2 | Recruiting | Alzheimer's Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781657) |
| August 10, 2026 | NCT07756294 | Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease | Wake Forest University Health Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756294) |
| August 3, 2026 | NCT07741071 | N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease | Haukeland University Hospital | Phase 2 | Recruiting | Alzheimer Disease (AD) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741071) |
| July 23, 2026 | NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | National Institute on Aging (NIA) | Phase 2 | Recruiting | Alzheimer's Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721467) |
| July 7, 2026 | NCT07688213 | A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease | Sanofi | Phase 2 | Recruiting | Dementia, Alzheimer's Type, Alzheimer's Disease | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688213) |
| May 28, 2026 | NCT07612150 | A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease | Merry Life Biomedical Co., Ltd. | Phase 2 | Not yet recruiting | Alzheimer Disease | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612150) |
| May 28, 2026 | NCT07611357 | \[18F\]F-AraG PET Imaging in Alzheimer's Disease | CellSight Technologies, Inc. | Phase 2 | Not yet recruiting | Alzheimer Disease (AD) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611357) |
| May 15, 2026 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Eli Lilly and Company | Phase 2 | Recruiting | Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589595) |
| April 28, 2026 | NCT07553338 | Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease | Weill Medical College of Cornell University | Phase 2 | Recruiting | Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553338) |
| April 6, 2026 | NCT07512362 | Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512362) |
| March 27, 2026 | NCT07496918 | Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices) | Massachusetts Institute of Technology | Phase 2 | Recruiting | Cognitively Healthy People, Alzheimer Disease | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07496918) |
| March 17, 2026 | NCT07477431 | Levetiracetam for Persons at Risk for Alzheimer's Disease | Sunnybrook Health Sciences Centre | Phase 2 | Recruiting | Hippocampal Hyperactivation, Prodromal Alzheimer Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477431) |
| February 10, 2026 | NCT07399171 | Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers | Halia Therapeutics, Inc. | Phase 2 | Recruiting | Alzheimers Disease | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07399171) |
| February 6, 2026 | NCT07392723 | ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392723) |
| December 12, 2025 | NCT07279740 | Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia | Sunnybrook Health Sciences Centre | Phase 2 | Recruiting | Alzheimer s Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease, Apathy, Apathy in Dementia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279740) |
| November 26, 2025 | NCT07252440 | A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease | Shanghai Auzone Biological Technology Co., Ltd. | Phase 2 | Recruiting | AD, Early Alzheimer's Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252440) |
| November 19, 2025 | NCT07236190 | Biomarker-based Trial of NPC-1 for Alzheimer's Pathology | Massachusetts General Hospital | Phase 2 | Recruiting | Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236190) |
| November 13, 2025 | NCT07228078 | Open-Label Extension Protocol to SNK01-AD01 Study | NKGen Biotech, Inc. | Phase 2 | Recruiting | Alzheimer Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228078) |
| October 20, 2025 | NCT07217912 | Daridorexant to Prevent Post-cardiotomy Delirium | University of Rochester | Phase 2 | Recruiting | Postoperative Cognitive Decline, Postoperative Delirium | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217912) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sunnybrook Health Sciences Centre | 3 |
| University of Colorado, Denver | 2 |
| St. Joseph's Hospital and Medical Center, Phoenix | 2 |
| Rutgers, The State University of New Jersey | 2 |
| University of Minnesota | 2 |
| Imperial College London | 2 |
| [NewAmsterdam Pharma](https://specstream.ai/data/clinical-trials/company/newamsterdam-pharma) | 1 |
| Lighthouse Pharmaceuticals, Inc. | 1 |
| Massachusetts Institute of Technology | 1 |
| Chinese University of Hong Kong | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| CellSight Technologies, Inc. | 1 |
| Stanford University | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| [Intra-Cellular Therapies, Inc.](https://specstream.ai/data/clinical-trials/company/intra-cellular-therapies-inc) | 1 |
| Medical University of Lodz | 1 |
| Brigham and Women's Hospital | 1 |
| Vanderbilt University Medical Center | 1 |
| MapLight Therapeutics | 1 |
| Neurology Office of South Florida | 1 |
| Plans4Care Inc | 1 |
| Shanghai Auzone Biological Technology Co., Ltd. | 1 |
| University of California, Davis | 1 |
| BeyondBio Inc. | 1 |
| NKGen Biotech, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 42 |
| Canada | 8 |
| Australia | 5 |
| China | 5 |
| South Korea | 5 |
| Spain | 4 |
| Argentina | 4 |
| Poland | 4 |
| Taiwan | 4 |
| United Kingdom | 3 |
| France | 3 |
| Norway | 3 |
| Germany | 2 |
| Bulgaria | 2 |
| Czechia | 2 |
| Italy | 2 |
| Romania | 2 |
| Serbia | 2 |
| Slovakia | 2 |
| Japan | 2 |
| Hong Kong | 1 |
| Croatia | 1 |
| Israel | 1 |
| Chile | 1 |
| Hungary | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Driving schools in the United States](https://specstream.ai/data/businesses/driving-schools/united-states)
- [Oncology practices in the United States](https://specstream.ai/data/businesses/oncology-practices/united-states)
- [Aesthetic medicine clinics in the United States](https://specstream.ai/data/businesses/aesthetic-medicine-clinics/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
